Zhejiang Medicine (600216.SH) released its semi-annual performance results, with a net profit attributable to shareholders of 673 million yuan, an increase of 113.52% year-on-year.

Zhici Finance APP News: Zhejiang Medicine (600216.SH) released its 2025 interim report. During the reporting period, the company achieved operating revenue of 4.323 billion yuan, a year-on-year decrease of 1.87%; net profit attributable to the parent company was 673 million yuan, a year-on-year increase of 113.52%; non-GAAP net profit was 665 million yuan, a year-on-year increase of 110.10%; basic earnings per share was 0.70 yuan.